Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients

Bianca Weinstock-Guttman, Robert Zivadinov, Jun Qu, Diane Cookfair, Xiaotao Duan, Eunjin Bang, Niels Bergsland, Sara Hussein, Mariya Cherneva, Laura Willis, Mari Heininen-Brown, Murali Ramanathan

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Purpose: The associations between vitamin D and MRI measures of brain tissue injury have not been previously investigated in multiple sclerosis (MS). This research evaluates the significance of vitamin D and its active metabolites in brain tissue injury and clinical disability in MS patients. Methods: The study population consisted of 193 MS patients (152 women and 41 men; mean age 46.1 (SD 8.4) years; disease duration 13.8 (SD 8.4) years). Serum levels of 25-hydroxyvitamin D3 (25(OH)VD3), 25-hydroxyvitamin D 2 (25(OH)VD2), 1α, 25-dihydroxyvitamin D3 (1, 25(OH)2VD3) and 24(R), 25-dihydroxyvitamin D 3 (24, 25(OH)2VD3) were measured using a novel capillary liquid-chromatography-mass spectrometry method. Disability was assessed with the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS). MRI measures included T2 lesion volume (LV), T1-LV and brain parenchymal fraction. The associations between deseasonalised levels of vitamin D metabolites and clinical and MRI measurements were assessed using regression analyses. Results: Lower deseasonalised levels of total 25(OH)VD (p=0.029), 25(OH)VD3 (p=0.032) and 24, 25(OH)2VD3 (p=0.005) were associated with higher MSSS. Similarly, lower deseasonalised levels of 24, 25(OH)2VD3 (p=0.012) were associated with higher EDSS. Higher values of the 25(OH)VD3 to 24, 25(OH) 2VD3 ratio were associated with higher MSSS (p=0.041) and lower brain parenchymal fraction (p=0.008). Conclusions: Vitamin D metabolites have protective associations with disability and brain atrophy in MS. In particular, the results indicate strong associations for the 24, 25(OH) 2VD3 metabolite, which has not been extensively investigated in MS patients.

Original languageEnglish
Pages (from-to)189-195
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume82
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Vitamin D
Multiple Sclerosis
Brain Injuries
25-Hydroxyvitamin D 2
Brain
24,25-Dihydroxyvitamin D 3
Calcifediol
Calcitriol
Liquid Chromatography
Atrophy
Mass Spectrometry
Regression Analysis
Serum
Research
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery

Cite this

Weinstock-Guttman, B., Zivadinov, R., Qu, J., Cookfair, D., Duan, X., Bang, E., ... Ramanathan, M. (2011). Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 82(2), 189-195. https://doi.org/10.1136/jnnp.2010.227942

Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. / Weinstock-Guttman, Bianca; Zivadinov, Robert; Qu, Jun; Cookfair, Diane; Duan, Xiaotao; Bang, Eunjin; Bergsland, Niels; Hussein, Sara; Cherneva, Mariya; Willis, Laura; Heininen-Brown, Mari; Ramanathan, Murali.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 82, No. 2, 02.2011, p. 189-195.

Research output: Contribution to journalArticle

Weinstock-Guttman, B, Zivadinov, R, Qu, J, Cookfair, D, Duan, X, Bang, E, Bergsland, N, Hussein, S, Cherneva, M, Willis, L, Heininen-Brown, M & Ramanathan, M 2011, 'Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients', Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 2, pp. 189-195. https://doi.org/10.1136/jnnp.2010.227942
Weinstock-Guttman, Bianca ; Zivadinov, Robert ; Qu, Jun ; Cookfair, Diane ; Duan, Xiaotao ; Bang, Eunjin ; Bergsland, Niels ; Hussein, Sara ; Cherneva, Mariya ; Willis, Laura ; Heininen-Brown, Mari ; Ramanathan, Murali. / Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. In: Journal of Neurology, Neurosurgery and Psychiatry. 2011 ; Vol. 82, No. 2. pp. 189-195.
@article{408d6299c37c47a99864e4e4c7eb4c8c,
title = "Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients",
abstract = "Purpose: The associations between vitamin D and MRI measures of brain tissue injury have not been previously investigated in multiple sclerosis (MS). This research evaluates the significance of vitamin D and its active metabolites in brain tissue injury and clinical disability in MS patients. Methods: The study population consisted of 193 MS patients (152 women and 41 men; mean age 46.1 (SD 8.4) years; disease duration 13.8 (SD 8.4) years). Serum levels of 25-hydroxyvitamin D3 (25(OH)VD3), 25-hydroxyvitamin D 2 (25(OH)VD2), 1α, 25-dihydroxyvitamin D3 (1, 25(OH)2VD3) and 24(R), 25-dihydroxyvitamin D 3 (24, 25(OH)2VD3) were measured using a novel capillary liquid-chromatography-mass spectrometry method. Disability was assessed with the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS). MRI measures included T2 lesion volume (LV), T1-LV and brain parenchymal fraction. The associations between deseasonalised levels of vitamin D metabolites and clinical and MRI measurements were assessed using regression analyses. Results: Lower deseasonalised levels of total 25(OH)VD (p=0.029), 25(OH)VD3 (p=0.032) and 24, 25(OH)2VD3 (p=0.005) were associated with higher MSSS. Similarly, lower deseasonalised levels of 24, 25(OH)2VD3 (p=0.012) were associated with higher EDSS. Higher values of the 25(OH)VD3 to 24, 25(OH) 2VD3 ratio were associated with higher MSSS (p=0.041) and lower brain parenchymal fraction (p=0.008). Conclusions: Vitamin D metabolites have protective associations with disability and brain atrophy in MS. In particular, the results indicate strong associations for the 24, 25(OH) 2VD3 metabolite, which has not been extensively investigated in MS patients.",
author = "Bianca Weinstock-Guttman and Robert Zivadinov and Jun Qu and Diane Cookfair and Xiaotao Duan and Eunjin Bang and Niels Bergsland and Sara Hussein and Mariya Cherneva and Laura Willis and Mari Heininen-Brown and Murali Ramanathan",
year = "2011",
month = "2",
doi = "10.1136/jnnp.2010.227942",
language = "English",
volume = "82",
pages = "189--195",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients

AU - Weinstock-Guttman, Bianca

AU - Zivadinov, Robert

AU - Qu, Jun

AU - Cookfair, Diane

AU - Duan, Xiaotao

AU - Bang, Eunjin

AU - Bergsland, Niels

AU - Hussein, Sara

AU - Cherneva, Mariya

AU - Willis, Laura

AU - Heininen-Brown, Mari

AU - Ramanathan, Murali

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: The associations between vitamin D and MRI measures of brain tissue injury have not been previously investigated in multiple sclerosis (MS). This research evaluates the significance of vitamin D and its active metabolites in brain tissue injury and clinical disability in MS patients. Methods: The study population consisted of 193 MS patients (152 women and 41 men; mean age 46.1 (SD 8.4) years; disease duration 13.8 (SD 8.4) years). Serum levels of 25-hydroxyvitamin D3 (25(OH)VD3), 25-hydroxyvitamin D 2 (25(OH)VD2), 1α, 25-dihydroxyvitamin D3 (1, 25(OH)2VD3) and 24(R), 25-dihydroxyvitamin D 3 (24, 25(OH)2VD3) were measured using a novel capillary liquid-chromatography-mass spectrometry method. Disability was assessed with the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS). MRI measures included T2 lesion volume (LV), T1-LV and brain parenchymal fraction. The associations between deseasonalised levels of vitamin D metabolites and clinical and MRI measurements were assessed using regression analyses. Results: Lower deseasonalised levels of total 25(OH)VD (p=0.029), 25(OH)VD3 (p=0.032) and 24, 25(OH)2VD3 (p=0.005) were associated with higher MSSS. Similarly, lower deseasonalised levels of 24, 25(OH)2VD3 (p=0.012) were associated with higher EDSS. Higher values of the 25(OH)VD3 to 24, 25(OH) 2VD3 ratio were associated with higher MSSS (p=0.041) and lower brain parenchymal fraction (p=0.008). Conclusions: Vitamin D metabolites have protective associations with disability and brain atrophy in MS. In particular, the results indicate strong associations for the 24, 25(OH) 2VD3 metabolite, which has not been extensively investigated in MS patients.

AB - Purpose: The associations between vitamin D and MRI measures of brain tissue injury have not been previously investigated in multiple sclerosis (MS). This research evaluates the significance of vitamin D and its active metabolites in brain tissue injury and clinical disability in MS patients. Methods: The study population consisted of 193 MS patients (152 women and 41 men; mean age 46.1 (SD 8.4) years; disease duration 13.8 (SD 8.4) years). Serum levels of 25-hydroxyvitamin D3 (25(OH)VD3), 25-hydroxyvitamin D 2 (25(OH)VD2), 1α, 25-dihydroxyvitamin D3 (1, 25(OH)2VD3) and 24(R), 25-dihydroxyvitamin D 3 (24, 25(OH)2VD3) were measured using a novel capillary liquid-chromatography-mass spectrometry method. Disability was assessed with the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS). MRI measures included T2 lesion volume (LV), T1-LV and brain parenchymal fraction. The associations between deseasonalised levels of vitamin D metabolites and clinical and MRI measurements were assessed using regression analyses. Results: Lower deseasonalised levels of total 25(OH)VD (p=0.029), 25(OH)VD3 (p=0.032) and 24, 25(OH)2VD3 (p=0.005) were associated with higher MSSS. Similarly, lower deseasonalised levels of 24, 25(OH)2VD3 (p=0.012) were associated with higher EDSS. Higher values of the 25(OH)VD3 to 24, 25(OH) 2VD3 ratio were associated with higher MSSS (p=0.041) and lower brain parenchymal fraction (p=0.008). Conclusions: Vitamin D metabolites have protective associations with disability and brain atrophy in MS. In particular, the results indicate strong associations for the 24, 25(OH) 2VD3 metabolite, which has not been extensively investigated in MS patients.

UR - http://www.scopus.com/inward/record.url?scp=78751580274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751580274&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2010.227942

DO - 10.1136/jnnp.2010.227942

M3 - Article

C2 - 21047880

AN - SCOPUS:78751580274

VL - 82

SP - 189

EP - 195

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 2

ER -